Cargando…
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
OBJECTIVE: To evaluate risks of disease reactivity during pregnancy and postpartum following rituximab (RTX) and natalizumab (NTZ) suspension in women with MS. METHODS: An observational cohort study of all women with MS disease onset before childbirth between 2006 and 2017. Women were identified thr...
Autores principales: | Razaz, Neda, Piehl, Fredrik, Frisell, Thomas, Langer-Gould, Annette M., McKay, Kyla A., Fink, Katharina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641107/ https://www.ncbi.nlm.nih.gov/pubmed/33087582 http://dx.doi.org/10.1212/NXI.0000000000000903 |
Ejemplares similares
-
Multiple sclerosis, disease-modifying drugs and risk for adverse
perinatal and pregnancy outcomes: Results from a population-based cohort
study
por: Fink, Katharina, et al.
Publicado: (2023) -
Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020) -
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021) -
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023) -
COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)